Literature DB >> 6187153

Pemphigus: an epidemiological study of patients treated in Finnish hospitals between 1969 and 1978.

J Hietanen, O P Salo.   

Abstract

Between 1969 and 1978, 44 pemphigus (p.) patients were treated in Finnish hospitals. The number of new cases was 36, giving an annual incidence of 0.76 cases per million inhabitants. The male/female ratio was 0.9:1. Nine patients had p. vulgaris (p.vu.); one p. vegetans (p.ve.); 9, p. foliaceus (p.fo.); 22, p. erythematodes (p.er.); and 3, p.NUD (p.NUD). One patient with p.er. also had myasthenia gravis. The mean age at onset was 57 1/2 years. The disease started in the mouth only in p.vu. (78% of cases) and in p.NUD (67%). Prednisone (or its derivatives) was most commonly used for systemic treatment, the mean initial dose being 61.4 mg/day. P.vu. and p.NUD required higher initial doses of prednisone and a longer duration of the high-dose treatment. The smallest mean daily dose of prednisone required to achieve a remission of at least 6 months was 5.2 mg. The mean duration of remission was 30 1/2 months. The frequency of side effects of systemic drug therapy was low (18%), possibly because only comparatively low doses of prednisone were used in Finland. The cause of death in 3 (6.8%) out of 44 patients was attributable either to p. itself or to its treatment. The mean annual number of hospitalization days for the whole material was 16.4 days and the mean annual number of hospital admissions 0.7.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6187153

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  16 in total

Review 1.  Pemphigus group: overview, epidemiology, mortality, and comorbidities.

Authors:  Khalaf Kridin
Journal:  Immunol Res       Date:  2018-04       Impact factor: 2.829

2.  Epidemiology of pemphigus in tehran, iran: a 20-year retrospective study.

Authors:  Hamid Reza Abdolsamadi; Shermin Abdollahzadeh; Pejman Bakianian Vaziri; Akram Beheshti; Elnaz Shafigh; Mohammad Vahedi
Journal:  J Dent Res Dent Clin Dent Prospects       Date:  2007-12-20

Review 3.  Autoimmune blistering diseases in females: a review.

Authors:  Cathy Y Zhao; Dédée F Murrell
Journal:  Int J Womens Dermatol       Date:  2015-02-26

4.  Involvement of Nail Apparatus in Pemphigus Vulgaris in Ethnic Poles Is Infrequent.

Authors:  Pawel Pietkiewicz; Monika Bowszyc-Dmochowska; Justyna Gornowicz-Porowska; Marian Dmochowski
Journal:  Front Med (Lausanne)       Date:  2018-08-14

5.  Pemphigus in the eastern region of Turkey.

Authors:  Ibrahim Halil Yavuz; Goknur Ozaydın Yavuz; Irfan Bayram; Serap Gunes Bilgili
Journal:  Postepy Dermatol Alergol       Date:  2019-08-30       Impact factor: 1.837

6.  Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.

Authors:  S M Langan; L Smeeth; R Hubbard; K M Fleming; C J P Smith; J West
Journal:  BMJ       Date:  2008-07-09

7.  Clinical and histological characterization of oral pemphigus lesions in patients with skin diseases: a cross sectional study from Sudan.

Authors:  Nada M Suliman; Anne N Åstrøm; Raouf W Ali; Hussein Salman; Anne C Johannessen
Journal:  BMC Oral Health       Date:  2013-11-21       Impact factor: 2.757

Review 8.  Reviewing putative industrial triggering in pemphigus: cluster of pemphigus in the area near the wastewater treatment plant.

Authors:  Paweł Pietkiewicz; Justyna Gornowicz-Porowska; Paweł Bartkiewicz; Monika Bowszyc-Dmochowska; Marian Dmochowski
Journal:  Postepy Dermatol Alergol       Date:  2017-05-29       Impact factor: 1.837

9.  The Risk of Depression in Patients with Pemphigus: A Nationwide Cohort Study in Taiwan.

Authors:  Yi-Min Hsu; Hsin-Yu Fang; Cheng-Li Lin; Shwn-Huey Shieh
Journal:  Int J Environ Res Public Health       Date:  2020-03-17       Impact factor: 3.390

10.  Nineteen-year retrospective evaluation of pemphigus in a single dermatology centre in Istanbul, Turkey.

Authors:  Mukaddes Kavala; İlkin Zindancı; Zafer Turkoglu; Burce Can Kuru; Emin Ozlu; Mehmet Simsek
Journal:  Postepy Dermatol Alergol       Date:  2020-03-09       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.